➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Johnson and Johnson
Dow
Merck
Mallinckrodt

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Insulin detemir recombinant - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for insulin detemir recombinant

Identify potential brand extensions & biosimilar entrants

SponsorPhase
First Affiliated Hospital Xi'an Jiaotong UniversityN/A
Minneapolis Medical Research FoundationN/A
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPhase 3

See all insulin detemir recombinant clinical trials

Recent Litigation for insulin detemir recombinant

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
NOVO NORDISK INC. v. SANDOZ INC.2020-06-04
Novo Nordisk Inc. v. Sandoz Inc.2020-06-03
Novo Nordisk Inc. v. Mylan Institutional LLC2019-08-20

See all insulin detemir recombinant litigation

PTAB Litigation
PetitionerDate
2014-01-23

See all insulin detemir recombinant litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin detemir recombinant Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin detemir recombinant Derived from Company Disclosures

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 2005-06-16 ⤷  Free Forever Trial D.C.P. AF 1988 A/S (DK) 2008-02-10 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 2005-06-16 ⤷  Free Forever Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 2005-06-16 ⤷  Free Forever Trial Novo Nordisk A/S (Bagsvaerd, DK) 2015-05-12 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 2005-06-16 ⤷  Free Forever Trial Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 2005-06-16 ⤷  Free Forever Trial Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
Novo Nordisk Inc LEVEMIR insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536 2005-06-16 ⤷  Free Forever Trial Novo Nordisk A/S (Bagsvaerd, DK) 2013-09-17 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

3) Low Certainty: US Patents for insulin detemir recombinant Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin detemir recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13C/038 Belgium ⤷  Free Forever Trial PRODUCT NAME: RYZODEG-INSULINE DEGLUDEC/INSULINE ASPARTE; AUTHORISATION NUMBER AND DATE: EU/1/12/806/001 20130121
C/GB13/037 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, COMPLEXES, OR SALTS THEREOF; REGISTERED: UK EU/1/12/807/001 20130123; UK EU/1/12/807/004 20130123; UK EU/1/12/807/005 20130123; UK EU/1/12/807/007 20130123; UK EU/1/12/807/008 20130123; UK EU/1/12/807/009 20130123; UK EU/1/12/807/012 20130123; UK EU/1/12/807/013 20130123; UK EU/1/12/807/015 20130123
13C/035 Belgium ⤷  Free Forever Trial PRODUCT NAME: TRESIBA-INSULINE DEGLUDEC; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001 20130121
2004005 Lithuania ⤷  Free Forever Trial PRODUCT NAME: INSULIN DETEMIR
40/2005 Austria ⤷  Free Forever Trial PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LÖSLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHÄLTNIS 50:50
34/2000 Austria ⤷  Free Forever Trial PRODUCT NAME: LANTUS - INSULIN GLARGIN
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKinsey
Boehringer Ingelheim
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.